International consensus guidance for management of myasthenia gravis by Sanders, Donald B. et al.
VIEWS & REVIEWS
Donald B. Sanders, MD*




Nils E. Gilhus, MD
Isabel Illa, MD
Nancy Kuntz, MD
















International consensus guidance for
management of myasthenia gravis
Executive summary
ABSTRACT
Objective: To develop formal consensus-based guidance for the management of myasthenia
gravis (MG).
Methods: In October 2013, theMyasthenia Gravis Foundation of America appointed a Task Force
to develop treatment guidance for MG, and a panel of 15 international experts was convened. The
RAND/UCLA appropriateness methodology was used to develop consensus guidance state-
ments. Definitions were developed for goals of treatment, minimal manifestations, remission, ocu-
lar MG, impending crisis, crisis, and refractory MG. An in-person panel meeting then determined
7 treatment topics to be addressed. Initial guidance statements were developed from literature
summaries. Three rounds of anonymous e-mail votes were used to attain consensus on guidance
statements modified on the basis of panel input.
Results: Guidance statements were developed for symptomatic and immunosuppressive treat-
ments, IV immunoglobulin and plasma exchange, management of impending and manifest myas-
thenic crisis, thymectomy, juvenile MG, MG associated with antibodies to muscle-specific
tyrosine kinase, and MG in pregnancy.
Conclusion: This is an international formal consensus of MG experts intended to be a guide for
clinicians caring for patients with MG worldwide. Neurology® 2016;87:419–425
GLOSSARY
AChR 5 acetylcholine receptor; ChEI 5 cholinesterase inhibitor; CTCAE 5 Common Terminology Criteria for Adverse
Events; FDA 5 Food and Drug Administration; IS 5 immunosuppressive; IVIg 5 IV immunoglobulin; JMG 5 juvenile myas-
thenia gravis; MG 5 myasthenia gravis; MGFA 5 Myasthenia Gravis Foundation of America; MMS 5 minimal manifestation
status; MuSK 5 muscle-specific tyrosine kinase; PIS 5 Post-Intervention Status; PLEX 5 plasma exchange; RAM 5 RAND/
UCLA Appropriateness Method; RCT 5 randomized controlled trial.
Acquired myasthenia gravis (MG) is a disorder of neuromuscular transmission, resulting from
binding of autoantibodies to components of the neuromuscular junction, most commonly
the acetylcholine receptor (AChR). The incidence ranges from 0.3 to 2.8 per 100,000,1 and
it is estimated to affect more than 700,000 people worldwide.
The increasing use of immunomodulating therapies has been a major factor in improving the
prognosis for patients with MG in recent years.2 The various treatment options must be weighed
in the context of individual patient factors.
Why do we need MG guidance treatment statements? Although there is widespread agreement on the use of many
treatments for MG, there is no internationally accepted standard of care. Because MG is heterogeneous, no one
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treatment approach is best for all patients. Few physi-
cians treat enough patients with MG to be comfort-
able with all available treatments. Given its
heterogeneity, the few randomized controlled trials
(RCTs) in MG have limited generalizability, while
uncontrolled trials are limited by potential bias.
Hence, an effort to develop consensus among interna-
tional experts was undertaken to guide clinicians
worldwide on the multifaceted approach to managing
MG. This summary condenses the extensive back-
ground information in the full guidance statements,
available on theNeurology®Web site at Neurology.org.
Panel constitution and method of expert consensus. In
October 2013, a Task Force of the Myasthenia
Gravis Foundation of America (MGFA) convened
a panel of 15 international experts in MG to develop
treatment guidance statements based on formalized
consensus. The panel was chosen to represent the
breadth of knowledge and experience and a wide vari-
ety of opinions from MG experts internationally.
Development of preliminary definitions.The panel initially
voted on definitions that formed the foundation for sub-
sequent guidance treatment statements: goals of treat-
ment, remission, ocular MG, impending and manifest
myasthenic crises, and refractory MG.
The Task Force co-chairs (D.B.S., G.I.W.)
drafted initial definitions based on available litera-
ture.3 These were sent by e-mail to the panelists,
who were asked to vote yes or no on each, and to
provide modifications if they did not agree. Panelists
were instructed not to discuss the definitions among
themselves, and to send their votes only to the facil-
itator (P.N.). A simple consensus was used ($80% of
panelists voting yes).
Definitions not achieving consensus were modi-
fied based on the panelists’ suggestions and the mod-
ified definitions and discussions were shared with the
panel for subsequent voting rounds.
Development of guidance treatment statements. The
following were agreed upon a priori:
1. Treatment costs and availability would not be con-
sidered, as it is not possible to make international
consensus statements specific for all countries.
2. Clinical examination is assumed to have been per-
formed by physicians skilled in the evaluation of
neuromuscular disease.
3. The MGFA Clinical Classification, including
remission, refers to the state of the patient at the
time of evaluation.
A formal systematic review of the literature was
not performed. The Task Force co-chairs and facilita-
tor drafted initial guidance statements based on liter-
ature cited in recent national and regional MG
treatment guidelines,4–9 supplemented by other
literature.
Guidance statements were developed for the
following:
1. Symptomatic and immunosuppressive (IS)
treatments
2. IV immunoglobulin (IVIg) and plasma exchange
(PLEX)
3. Impending and manifest myasthenic crisis
4. Thymectomy
5. Juvenile MG (JMG)
6. MG with antibodies to muscle-specific tyrosine
kinase (MuSK-MG)
7. MG in pregnancy
Voting process for consensus guidance treatment
statements. We used the RAND/UCLA Appropriate-
ness Method (RAM) for formal consensus to quantify
agreement.10 RAM uses a multi-round modified
Delphi process to obtain a quantitative assessment
that reflects the judgment of an expert group.
Appropriateness refers to the relative benefit vs
harm of the intervention. We obtained anonymous
votes and feedback on each draft statement from the
panelists, who rated each for appropriateness on a 9-
point scale (1–3 inappropriate, 4–6 uncertain, and 7–
9 appropriate). Panelists responded by e-mail to the
facilitator, who tallied the votes and collated the
discussions. Following each round of voting,
statements were modified by the Task Force co-
chairs and facilitator based on the panel feedback.
Statements that did not achieve consensus within 3
rounds were excluded.
For statements on symptomatic and IS therapies
and thymectomy, an initial round of e-mail voting
was followed by a meeting in Durham, North
Carolina, on March 1, 2014. During this meeting,
statements that had undergone prior voting by
e-mail were refined with panel input, and a second
round of voting was completed. All subsequent voting
was by e-mail.
The level of appropriateness and presence of agree-
ment were determined for each statement as per RAM.10
RESULTS All definitions below obtained simple con-
sensus and all guidance statements below were agreed
upon as being appropriate by the panel. Literature
summaries and tables for medication dosing guidance
and medication cautions are available as supplemental
data at Neurology.org.
Preliminary definitions.
1. Goals for the treatment of MG. MGFA Task Force
Post-Intervention Status (PIS) classification Minimal
Manifestation Status (MMS) or better,3 with no more
than grade 1 Common Terminology Criteria for
Adverse Events (CTCAE) medication side effects.11
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MMS: The patient has no symptoms or functional
limitations from MG but has some weakness on
examination of some muscles. This class recognizes
that some patients who otherwise meet the definition
of remission have mild weakness.
CTCAE grade 1 medication side effects: asymp-
tomatic or only mild symptoms; intervention not
indicated.
2. Definition of remission. The patient has no symp-
toms or signs of MG. Weakness of eyelid closure is
accepted, but there is no weakness of any other mus-
cle on careful examination. Patients taking cholines-
terase inhibitors (ChEIs) every day with reasonable
evidence to support symptomatic benefit are therefore
excluded from this category.
3. Definition of ocular MG (based on dysfunction due to
MG at a specified point in time, and not dependent upon the
duration of disease).MGFA Class I3: Any ocular muscle
weakness. May have weakness of eye closure.
Strength in all other facial, bulbar, and limb muscles
is normal. (It is recognized that some patients report
fatigue when strength testing is normal. The physi-
cian should use clinical judgment in attributing
fatigue to generalized MG in the absence of objec-
tive nonocular weakness).
4. Definition of impending myasthenic crisis. Rapid clin-
ical worsening of MG that, in the opinion of the
treating physician, could lead to crisis in the short
term (days to weeks).
5. Definition of manifest myasthenic crisis (the concept of
crisis focuses on the clinical implications—it represents a seri-
ous, life-threatening, rapid worsening of MG and potential
airway compromise from ventilatory or bulbar dysfunction).
MGFA Class V3: Worsening of myasthenic weakness
requiring intubation or noninvasive ventilation to
avoid intubation, except when these measures are
employed during routine postoperative management
(the use of a feeding tube without intubation places
the patient in MGFA Class IVB3).
6. Definition of refractory MG. PIS3 is unchanged or
worse after corticosteroids and at least 2 other IS
agents, used in adequate doses for an adequate dura-
tion, with persistent symptoms or side effects that limit
functioning, as defined by patient and physician.
Consensus guidance treatment statements.
Symptomatic and IS treatment of MG.
1. Pyridostigmine should be part of the initial treat-
ment in most patients with MG. Pyridostigmine
dose should be adjusted as needed based on symp-
toms. The ability to discontinue pyridostigmine can
be an indicator that the patient has met treatment
goals and may guide the tapering of other therapies.
Corticosteroids or IS therapy should be used in all
patients withMGwho have not met treatment goals
after an adequate trial of pyridostigmine.
2. A nonsteroidal IS agent should be used alone when
corticosteroids are contraindicated or refused.
A nonsteroidal IS agent should be used initially
in conjunction with corticosteroids when the risk
of steroid side effects is high based on medical
comorbidities. A nonsteroidal IS agent should be
added to corticosteroids when:
a. Steroid side effects, deemed significant by the
patient or the treating physician, develop;
b. Response to an adequate trial (table e-1) of cor-
ticosteroids is inadequate; or
c. The corticosteroid dose cannot be reduced due
to symptom relapse.
3. Nonsteroidal IS agents that can be used in MG
include azathioprine, cyclosporine, mycophenolate
mofetil, methotrexate, and tacrolimus. The follow-
ing factors should be considered in selecting
among these agents:
a. There is widespread variation in practice with
respect to choice of IS agent since there is little
literature comparing them.
b. Expert consensus and some RCT evidence sup-
port the use of azathioprine as a first-line IS
agent in MG.
c. Evidence from RCTs supports the use of cyclo-
sporine in MG, but potential serious adverse
effects and drug interactions limit its use.
d. Although available RCT evidence does not sup-
port the use of mycophenolate and tacrolimus in
MG, both are widely used, and one or both are
recommended in several national MG treatment
guidelines.4–7
4. Patients with refractory MG should be referred to
a physician or a center with expertise in manage-
ment of MG. In addition to the previously men-
tioned IS agents, the following therapies may also
be used in refractory MG:
a. Chronic IVIg and chronic PLEX (see IVIg and
PLEX, no. 6);
b. Cyclophosphamide;
c. Rituximab, for which evidence of efficacy is
building, but for which formal consensus could
not be reached.
5. IS agent dosage and duration of treatment
a. Once patients achieve treatment goals, the cor-
ticosteroid dose should be gradually tapered. In
many patients, continuing a low dose of cortico-
steroids long-term can help to maintain the
treatment goal.
b. For nonsteroidal IS agents, once treatment goals
have been achieved and maintained for 6
months to 2 years, the IS dose should be tapered
slowly to the minimal effective amount. Dosage
adjustments should be made no more frequently
than every 3–6 months (table e-1).
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c. Tapering of IS drugs is associated with risk of
relapse, which may necessitate upward adjust-
ments in dose. The risk of relapse is higher in
patients who are symptomatic, or after rapid taper.
d. It is usually necessary to maintain some immu-
nosuppression for many years, sometimes for
life.
6. Patients must be monitored for potential adverse
effects and complications from IS drugs. Changing
to an alternative IS agent should be considered if
adverse effects and complications are medically sig-
nificant or create undue hardship for the patient.
IVIg and PLEX.
1. PLEX and IVIg are appropriately used as short-
term treatments in patients with MG with life-
threatening signs such as respiratory insufficiency
or dysphagia; in preparation for surgery in patients
with significant bulbar dysfunction; when a rapid
response to treatment is needed; when other treat-
ments are insufficiently effective; and prior to
beginning corticosteroids if deemed necessary to
prevent or minimize exacerbations.
2. The choice between PLEX and IVIg depends on
individual patient factors (e.g., PLEX cannot be
used in patients with sepsis and IVIg cannot be used
in renal failure) and on the availability of each.
3. IVIg and PLEX are probably equally effective in
the treatment of severe generalized MG.
4. The efficacy of IVIg is less certain in milder MG or
in ocular MG.
5. PLEX may be more effective than IVIg in MuSK-
MG.
6. The use of IVIg as maintenance therapy can be con-
sidered for patients with refractoryMG or for those in
whom IS agents are relatively contraindicated.
Impending and manifest myasthenic crisis. Impending and
manifest myasthenic crisis are emergent situations
requiring aggressive management and supportive
care.
Although cholinergic crises are now rare, excessive
ChEI cannot be completely excluded as a cause of
clinical worsening. Also, ChEIs increase airway secre-
tions, which may exacerbate breathing difficulties.
PLEX and IVIg are the mainstay of management
in myasthenic crisis.
1. Impending crisis requires hospital admission and
close observation of respiratory and bulbar func-
tion, with the ability to transfer to an intensive care
unit if it progresses to manifest crisis. Myasthenic
crisis requires admission to an intensive care or
step-down unit to monitor for or manage respira-
tory failure and bulbar dysfunction.
2. PLEX and IVIg are used as short-term treatment
for impending and manifest myasthenic crisis and
in patients with significant respiratory or bulbar
dysfunction. Corticosteroids or other IS agents
are often started at the same time to achieve a sus-
tained clinical response. (Because corticosteroids
may cause transient worsening of myasthenic
weakness, it may be appropriate to wait several
days for PLEX or IVIg to have a beneficial effect
before starting corticosteroids).
3. Although clinical trials suggest that IVIg and PLEX
are equally effective in the treatment of impending
or manifest myasthenic crisis, expert consensus
suggests that PLEX is more effective and works
more quickly. The choice between the 2 therapies
depends on patient comorbidity (e.g., PLEX can-
not be used in sepsis and IVIg is contraindicated in
hypercoagulable states, renal failure, or hypersensi-
tivity to immunoglobulin) and other factors,
including availability. A greater risk of hemody-
namic and venous access complications with PLEX
should also be considered in the decision (many
complications of PLEX are related to route of
access and may be minimized by using peripheral
rather than central venous access).
Thymectomy in MG.
1. In non-thymomatous MG, thymectomy is per-
formed as an option to potentially avoid
or minimize the dose or duration of immunother-
apy, or if patients fail to respond to an initial trial of
immunotherapy or have intolerable side-effects
from that therapy. Because of the long delay in
onset of effect, thymectomy for MG is an elective
procedure. It should be performed when the
patient is stable and deemed safe to undergo a pro-
cedure where postoperative pain and mechanical
factors can limit respiratory function.
2. The value of thymectomy in the treatment of pre-
pubertal patients with MG is unclear, but thymec-
tomy should be considered in children with
generalized AChR antibody–positive MG:
a. If the response to pyridostigmine and IS therapy
is unsatisfactory; or
b. In order to avoid potential complications of IS
therapy.
For children diagnosed with seronegative general-
ized MG, the possibility of a congenital myasthenic
syndrome or other neuromuscular condition should
be entertained, and evaluation at a center specializing
in neuromuscular diseases is of value prior to
thymectomy.
3. With rare exceptions, all patients with MG with
thymoma should undergo surgery to remove the
tumor. Removal of the thymoma is performed to
rid the patient of the tumor and may not produce
improvement in MG. All thymus tissue should be
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removed along with the tumor. Further treatment
of thymoma will be dictated by histologic classifi-
cation and degree of surgical excision. Incom-
pletely resected thymomas should be managed
after surgery with an interdisciplinary treatment
approach (radiotherapy, chemotherapy).
4. In elderly or multimorbid patients with thymoma,
palliative radiation therapy can be considered in
the appropriate clinical setting. Small thymomas
may be followed without treatment unless they
are enlarging or become symptomatic.
5. Endoscopic and robotic approaches to thymectomy
are increasingly performed and have a good track
record for safety in experienced centers. Data from
randomized, controlled comparison studies are not
available. Based on comparisons across studies, less
invasive thymectomy approaches appear to yield
similar results to more aggressive approaches.
6. Thymectomy may be considered in patients with
generalized MG without detectable AChR anti-
bodies if they fail to respond adequately to IS ther-
apy, or to avoid/minimize intolerable adverse
effects from IS therapy. Current evidence does
not support an indication for thymectomy in pa-
tients with MuSK, LRP4, or agrin antibodies.
Juvenile MG (see also Thymectomy in MG, no. 2).
1. Children with acquired autoimmune ocular MG
are more likely than adults to go into spontaneous
remission. Thus, young children with only ocular
symptoms of MG can be treated initially with pyr-
idostigmine. Immunotherapy can be initiated if
goals of therapy are not met.
2. Children are at particular risk of steroid side effects,
including growth failure, poor bone mineralization,
and susceptibility to infection, due in part to a delay
in live vaccinations. Long-term treatment with cor-
ticosteroids should use the lowest effective dose
to minimize side effects.
3. Maintenance PLEX or IVIg are alternatives to IS
drugs in JMG.
MG with MuSK antibodies.
1. Many patients with MuSK-MG respond poorly to
ChEIs, and conventional pyridostigmine doses fre-
quently induce side effects.
2. Patients with MuSK-MG appear to respond well to
corticosteroids and to many steroid-sparing IS
agents. They tend to remain dependent on predni-
sone despite concomitant treatment with steroid-
sparing agents.
3. MuSK-MG responds well to PLEX, while IVIg
seems to be less effective.
4. Rituximab should be considered as an early thera-
peutic option in patients with MuSK-MG who have
an unsatisfactory response to initial immunotherapy.
MG in pregnancy.
1. Planning for pregnancy should be instituted well in
advance to allow time for optimization of myasthenic
clinical status and to minimize risks to the fetus.
2. Multidisciplinary communication among relevant
specialists should occur throughout pregnancy,
during delivery, and in the postpartum period.
3. Provided that their myasthenia is under good con-
trol before pregnancy, the majority of women can
be reassured that they will remain stable through-
out pregnancy. If worsening occurs, it may be
more likely during the first few months after
delivery.
4. Oral pyridostigmine is the first-line treatment dur-
ing pregnancy. IV ChEIs may produce uterine con-
tractions and should not be used during pregnancy.
5. Thymectomy should be postponed until after preg-
nancy as benefit is unlikely to occur during
pregnancy.
6. Chest CT without contrast can be performed safely
during pregnancy, although the risks of radiation
to the fetus need to be carefully considered. Unless
there is a compelling indication, postponement of
diagnostic CT until after delivery is preferable.
7. Prednisone is the IS agent of choice during
pregnancy.
8. Current information indicates that azathioprine
and cyclosporine are relatively safe in expectant
mothers who are not satisfactorily controlled with
or cannot tolerate corticosteroids. Current evidence
indicates that mycophenolate mofetil and metho-
trexate increase the risk of teratogenicity and are
contraindicated during pregnancy. (These agents
previously carried Food and Drug Administration
[FDA] Category C (cyclosporine), D (azathioprine
and mycophenolate mofetil), and X (methotrexate)
ratings. The FDA has recently discontinued this
rating system, and replaced it with a summary of
the risks of using a drug during pregnancy and
breastfeeding, along with supporting data and “rel-
evant information to help health care providers
make prescribing and counseling decisions”12).
Although this statement achieved consensus, there was
a strong minority opinion against the use of azathio-
prine in pregnancy. Azathioprine is the nonsteroidal
IS of choice for MG in pregnancy in Europe but is
considered high risk in the United States. This differ-
ence is based on a small number of animal studies and
case reports.
9. PLEX or IVIg are useful when a prompt, although
temporary, response is required during pregnancy.
Careful consideration of both maternal and fetal
issues, weighing the risks of these treatments
against the requirement for use during pregnancy
and their potential benefits, is required.
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10. Spontaneous vaginal delivery should be the
objective and is actively encouraged.
11. Magnesium sulfate is not recommended for
management of eclampsia in MG because of
its neuromuscular blocking effects; barbiturates
or phenytoin usually provide adequate
treatment.
12. All babies born to myasthenic mothers should
be examined for evidence of transient myas-
thenic weakness, even if the mother’s myasthe-
nia is well-controlled, and should have rapid
access to neonatal critical care support.
DISCUSSION We have developed international guid-
ance statements for the management of JMG and
adult MG. We utilized recent national guidelines and
a regional European guideline to assemble a foundation
of literature, supplementing their comprehensive litera-
ture reviews with additional articles identified by panel-
ists. After reaching agreement on the treatment goals,
a 3-round anonymous modified Delphi voting process
was used to obtain consensus on guidance statements.
A limitation of consensus-based processes is that
subconscious or conscious selection of like-minded
panel members may result in opinions that are not rep-
resentative of MG experts. This issue was addressed by
selecting an international panel with variations in prac-
tice and by using a formal consensus process.
Recognizing the variability of practice patterns and
availability of treatment modalities, these statements
are not absolute recommendations for management,
but are intended as a guide for the clinician. They
are also not intended for establishing payment poli-
cies or drug tiering by payers.
This is a living document that will require updates
as the MG treatment theater continues to evolve.
Despite the limitations of consensus-based methods,
these guidance statements reflect an up-to-date expert
consensus to guide clinicians worldwide who strive to
optimize function and quality of life for their patients
with MG, especially for those who practice in parts of
the world that do not have the resources to develop
local treatment guidelines. Any future trial of treat-
ment that provides relevant information will merit
review of these guidance statements.
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